Peptonic Medical (PMED) Q1 2025 earnings summary

Executive summary

• Q1 2025 focused on restructuring for profitability, including a company reorganization and cost reductions.

• Full-scale launch of VagiVital in the US and two new product launches in the Nordics marked strategic milestones.

• Application for company reorganization (rekonstruktion) was approved in March to address financial pressures and ensure long-term viability.

Financial highlights

• Net sales for Q1 2025 were 3,758 KSEK, down from 10,808 KSEK year-over-year due to divestments and structural changes.

• Gross profit was 2,165 KSEK (gross margin 58%), up from 55% last year, reflecting a higher share of Nordic sales.

• Operating loss improved to -7,459 KSEK from -10,398 KSEK year-over-year.

• EPS was -0.001 SEK, compared to -0.007 SEK in Q1 2024.

• Cash and cash equivalents at period end were 6,606 KSEK, with 5,373 KSEK under the control of the reorganization administrator.

Outlook and guidance

• The company expects the reorganization, new equity, and operational measures to enable continued operations and long-term survival.

• US market launch and new product introductions are expected to drive future growth.